|
US5851795A
(en)
|
1991-06-27 |
1998-12-22 |
Bristol-Myers Squibb Company |
Soluble CTLA4 molecules and uses thereof
|
|
US6682736B1
(en)
|
1998-12-23 |
2004-01-27 |
Abgenix, Inc. |
Human monoclonal antibodies to CTLA-4
|
|
US7109003B2
(en)
|
1998-12-23 |
2006-09-19 |
Abgenix, Inc. |
Methods for expressing and recovering human monoclonal antibodies to CTLA-4
|
|
US6467202B1
(en)
|
1999-07-01 |
2002-10-22 |
Bucyrus International, Inc. |
Dynamically active dipper door mechanism
|
|
NZ517202A
(en)
*
|
1999-08-24 |
2004-05-28 |
Medarex Inc |
Human CTLA-4 antibodies and their uses
|
|
US7605238B2
(en)
|
1999-08-24 |
2009-10-20 |
Medarex, Inc. |
Human CTLA-4 antibodies and their uses
|
|
WO2001058459A1
(fr)
|
2000-02-14 |
2001-08-16 |
Mitsubishi Pharma Corporation |
Remedes contre l'hepatite c
|
|
EP1471938A4
(en)
|
2002-01-09 |
2008-03-05 |
Medarex Inc |
HUMAN MONOCLONAL ANTIBODIES AGAINST CD30
|
|
NZ536420A
(en)
|
2002-04-12 |
2008-04-30 |
Medarex Inc |
Methods of treatment using CTLA-4 antibodies
|
|
US6981720B2
(en)
*
|
2003-11-07 |
2006-01-03 |
Agilent Technologies, Inc. |
Tapered ceramic GC fitting and assembly
|
|
WO2005051299A2
(en)
|
2003-11-19 |
2005-06-09 |
Dyax Corp. |
Metalloproteinase-binding proteins
|
|
CA2575791A1
(en)
|
2004-08-03 |
2006-02-16 |
Dyax Corp. |
Hk1-binding proteins
|
|
WO2006029219A2
(en)
|
2004-09-08 |
2006-03-16 |
Ohio State University Research Foundation |
Human monoclonal anti-ctla4 antibodies in cancer treatment
|
|
MX2007003533A
(es)
|
2004-10-01 |
2007-05-23 |
Medarex Inc |
Metodos de tratar linfomas cd30 positivas.
|
|
AU2005300315A1
(en)
|
2004-11-04 |
2006-05-11 |
Pfizer Products Inc. |
CTLA-4 antibody and aromatase inhibitor or combination treatment for breast cancer
|
|
US8207303B2
(en)
|
2005-02-18 |
2012-06-26 |
Medarex, Inc. |
Monoclonal antibodies against CD30 lacking in fucosyl residues
|
|
EP1865986B1
(en)
|
2005-03-08 |
2016-02-17 |
Pfizer Products Inc. |
Anti-ctla-4 antibody compositions
|
|
MX2007010603A
(es)
|
2005-03-23 |
2007-10-18 |
Pfizer Prod Inc |
Terapia de cancer de prostata con anticuerpos contra ctla4 y terapia hormonal.
|
|
CA2602316A1
(en)
|
2005-03-23 |
2006-09-28 |
Pfizer Products Inc. |
Anti-ctla4 antibody and indolinone combination therapy for treatment of cancer
|
|
JP2008546716A
(ja)
|
2005-06-17 |
2008-12-25 |
バイオジェン・アイデック・エムエイ・インコーポレイテッド |
抗ＧＦＲα３抗体
|
|
KR101704734B1
(ko)
|
2005-07-01 |
2017-02-09 |
이. 알. 스퀴부 앤드 선즈, 엘.엘.씨. |
예정 사멸 리간드 1 (피디-엘1)에 대한 인간 모노클로날 항체
|
|
WO2007008463A2
(en)
|
2005-07-07 |
2007-01-18 |
Coley Pharmaceutical Group, Inc. |
Anti-ctla-4 antibody and cpg-motif-containing synthetic oligodeoxynucleotide combination therapy for cancer treatment
|
|
SI1904104T1
(sl)
|
2005-07-08 |
2013-12-31 |
Biogen Idec Ma Inc. |
Protitelesa SP35 in njihova uporaba
|
|
US20100021473A1
(en)
|
2005-12-06 |
2010-01-28 |
Domantis Limited |
Bispecific Ligands With Binding Specificity to Cell Surface Targets and Methods of Use Therefor
|
|
NZ568016A
(en)
|
2005-12-07 |
2011-12-22 |
Medarex Inc |
CTLA-4 antibody dosage escalation regimens
|
|
US20090175886A1
(en)
|
2006-01-17 |
2009-07-09 |
Medarex, Inc. |
Monoclonal antibodies against cd30 lacking in fucosyl and xylosyl residues
|
|
EP2004685A4
(en)
|
2006-03-22 |
2009-04-29 |
Genimmune N V |
HEPATITIS C VIRUS NEUTRALIZING ANTIBODIES
|
|
WO2007113648A2
(en)
*
|
2006-04-05 |
2007-10-11 |
Pfizer Products Inc. |
Ctla4 antibody combination therapy
|
|
AU2007234733A1
(en)
|
2006-04-07 |
2007-10-18 |
The Government Of The United States Of America As Represented By The Secretary, Department Of Health And Human Services |
Antibody compositions and methods for treatment of neoplastic disease
|
|
WO2009077483A1
(en)
|
2007-12-14 |
2009-06-25 |
Novo Nordisk A/S |
Antibodies against human nkg2d and uses thereof
|
|
WO2008082651A2
(en)
|
2006-12-29 |
2008-07-10 |
Abbott Laboratories |
Dual-specific il-1a/ il-1b antibodies
|
|
HUE033325T2
(en)
|
2007-01-05 |
2017-11-28 |
Univ Zuerich |
Anti-beta-amyloid binder antibodies and their use
|
|
HRP20140049T1
(hr)
|
2007-01-05 |
2014-02-28 |
University Of Zürich |
Anti beta-amiloid antitijela i njihova upotreba
|
|
US8449886B2
(en)
|
2008-01-08 |
2013-05-28 |
Bristol-Myers Squibb Company |
Combination of anti-CTLA4 antibody with tubulin modulating agents for the treatment of proliferative diseases
|
|
WO2009100140A1
(en)
|
2008-02-04 |
2009-08-13 |
Medarex, Inc. |
Anti-clta-4 antibodies with reduced blocking of binding of ctla-4 to b7 and uses thereof
|
|
US8273351B2
(en)
*
|
2008-04-25 |
2012-09-25 |
Dyax Corp. |
Fc receptor binding proteins
|
|
WO2010004434A2
(en)
|
2008-07-09 |
2010-01-14 |
University Of Zurich |
Method of promoting neurogenesis
|
|
WO2010014784A2
(en)
|
2008-08-01 |
2010-02-04 |
Bristol-Myers Squibb Company |
Combination of anti-ctla4 antibody with diverse therapeutic regimens for the synergistic treatment of proliferative diseases
|
|
KR20110094307A
(ko)
|
2008-11-13 |
2011-08-23 |
펨타 파마슈티컬스, 인크. |
인간화된 항-ｉｌ-6 항체
|
|
GB0903325D0
(en)
|
2009-02-26 |
2009-04-08 |
Univ Aberdeen |
Antibody molecules
|
|
US8877199B2
(en)
|
2009-05-15 |
2014-11-04 |
The United States Of America, As Represented By The Secretary Of The Department Of Health And Human Services |
B cell surface reactive antibodies
|
|
US8435516B2
(en)
|
2009-10-12 |
2013-05-07 |
Pfizer Inc. |
Cancer treatment
|
|
US8993524B2
(en)
|
2010-03-05 |
2015-03-31 |
The Johns Hopkins University |
Compositions and methods for targeted immunomodulatory antibodies and fusion proteins
|
|
KR20130096731A
(ko)
*
|
2010-09-08 |
2013-08-30 |
할로자임, 아이엔씨 |
조건부 활성 치료적 단백질을 평가，확인 또는 진화시키는 방법
|
|
GB201103955D0
(en)
|
2011-03-09 |
2011-04-20 |
Antitope Ltd |
Antibodies
|
|
WO2012163519A1
(en)
|
2011-05-27 |
2012-12-06 |
Dutalys |
Antibodies with improved folding stability
|
|
KR102119840B1
(ko)
|
2011-07-11 |
2020-06-09 |
아이크노스 사이언스 에스. 아. |
Ox40에 결합하는 항체 및 이들의 용도
|
|
US20150079100A1
(en)
|
2012-03-23 |
2015-03-19 |
Bristol-Myers Squibb Company |
Methods of treatments using ctla-4 antibodies
|
|
MX360368B
(es)
*
|
2012-04-27 |
2018-10-29 |
Bioatla Llc |
Regiones de anticuerpo modificado y sus usos.
|
|
WO2013165972A2
(en)
|
2012-04-30 |
2013-11-07 |
Cell Signaling Technology, Inc. |
Anti-hepatitis b virus antibodies and use thereof
|
|
PL3489254T3
(pl)
|
2012-04-30 |
2023-01-30 |
Biocon Limited |
Ukierunkowujące/immunomodulujące białko fuzyjne i sposoby jego otrzymywania
|
|
NZ704771A
(en)
*
|
2012-08-13 |
2018-02-23 |
Regeneron Pharma |
Anti-pcsk9 antibodies with ph-dependent binding characteristics
|
|
EP2928494A4
(en)
|
2012-12-07 |
2016-11-02 |
Biogen Internat Neuroscience Gmbh |
METHOD FOR REDUCING AMYLOIDER PLAQUE OF BRAIN WITH ANTI-ASS ANTIBODIES
|
|
EP2948475A2
(en)
|
2013-01-23 |
2015-12-02 |
AbbVie Inc. |
Methods and compositions for modulating an immune response
|
|
MY186864A
(en)
|
2013-03-12 |
2021-08-26 |
Biocon Ltd |
Fusion immunomodulatory proteins and methods for making same
|
|
MY156185A
(en)
|
2013-04-08 |
2016-01-19 |
Malaysian Palm Oil Board |
Gene controlling fruit color phenotype in palm
|
|
SG11201509595PA
(en)
|
2013-05-28 |
2015-12-30 |
Dcb Usa Llc |
Antibody locker for the inactivation of protein drug
|
|
EP3010934A4
(en)
|
2013-06-17 |
2017-01-11 |
The Johns Hopkins University |
Antibodies to human resistin
|
|
WO2014209804A1
(en)
|
2013-06-24 |
2014-12-31 |
Biomed Valley Discoveries, Inc. |
Bispecific antibodies
|
|
WO2015006475A1
(en)
|
2013-07-12 |
2015-01-15 |
Biogen Idec International Neuroscience Gmbh |
Genetic and image biomarkers associated with decline in cognitive measures and brain glucose metabolism in populations with alzheimer's disease or those susceptible to developing alzheimer's disease
|
|
TWI655207B
(zh)
|
2013-07-30 |
2019-04-01 |
再生元醫藥公司 |
抗活化素ａ之抗體及其用途
|
|
MX377714B
(es)
*
|
2013-10-18 |
2025-03-11 |
Regeneron Pharma |
Composiciones que comprenden una combinación de un antagonista de vegf y un anticuerpo anti-ctla-a.
|
|
KR102272932B1
(ko)
|
2013-10-25 |
2021-07-05 |
싸이오서스 테라퓨틱스 엘티디. |
이종 유전자로 무장된 종양살상 아데노바이러스
|
|
AU2014374055B2
(en)
|
2013-12-30 |
2018-11-08 |
Epimab Biotherapeutics Inc. |
Fabs-in-tandem immunoglobulin and uses thereof
|
|
TWI681969B
(zh)
|
2014-01-23 |
2020-01-11 |
美商再生元醫藥公司 |
針對ｐｄ-１的人類抗體
|
|
US10933106B2
(en)
|
2014-02-25 |
2021-03-02 |
Deutsches Krebsforschungszentrum |
RNA viruses for immunovirotherapy
|
|
GB201406608D0
(en)
|
2014-04-12 |
2014-05-28 |
Psioxus Therapeutics Ltd |
Virus
|
|
CN104292334B
(zh)
*
|
2014-04-25 |
2018-11-27 |
河南省健康伟业生物医药研究股份有限公司 |
一种全人源抗ctla-4单克隆抗体、制备方法及应用
|
|
JO3701B1
(ar)
|
2014-05-23 |
2021-01-31 |
Regeneron Pharma |
مضادات حيوية بشرية لمتلازمة الشرق الأوسط التنفسية - بروتين كورونا فيروس الشوكي
|
|
PL3151921T3
(pl)
|
2014-06-06 |
2020-02-28 |
Bristol-Myers Squibb Company |
Przeciwciała przeciwko receptorowi indukowanego glukokortykoidami czynnika martwicy nowotworu (gitr) i ich zastosowania
|
|
WO2016022021A1
(en)
|
2014-08-04 |
2016-02-11 |
Acgt Sdn Bhd |
Sequence linked to fruit coat trait
|
|
KR20170044194A
(ko)
|
2014-08-27 |
2017-04-24 |
싸이오서스 테라퓨틱스 엘티디. |
아데노바이러스의 제조를 위한 공정
|
|
EP3186281B1
(en)
|
2014-08-28 |
2019-04-10 |
Halozyme, Inc. |
Combination therapy with a hyaluronan-degrading enzyme and an immune checkpoint inhibitor
|
|
US10513699B2
(en)
|
2014-09-03 |
2019-12-24 |
Bioatla, Llc |
Discovering and producing conditionally active biologic proteins in the same eukaryotic cell production hosts
|
|
WO2016059602A2
(en)
|
2014-10-16 |
2016-04-21 |
Glaxo Group Limited |
Methods of treating cancer and related compositions
|
|
WO2016077505A2
(en)
|
2014-11-11 |
2016-05-19 |
Amunix Operating Inc. |
Targeted xten conjugate compositions and methods of making same
|
|
WO2016090337A1
(en)
|
2014-12-05 |
2016-06-09 |
Memorial Sloan-Kettering Cancer Center |
Chimeric antigen receptors targeting fc receptor-like 5 and uses thereof
|
|
TWI710573B
(zh)
|
2015-01-26 |
2020-11-21 |
美商再生元醫藥公司 |
抗伊波拉病毒醣蛋白之人類抗體
|
|
CN114014930A
(zh)
*
|
2015-02-13 |
2022-02-08 |
索伦托药业有限公司 |
结合ctla4的抗体治疗剂
|
|
US10227411B2
(en)
|
2015-03-05 |
2019-03-12 |
Xencor, Inc. |
Modulation of T cells with bispecific antibodies and FC fusions
|
|
EP3991748A3
(en)
|
2015-04-07 |
2022-08-24 |
Alector LLC |
Anti-sortilin antibodies and methods of use thereof
|
|
CN108137669B
(zh)
|
2015-05-18 |
2023-02-17 |
优瑞科生物技术公司 |
抗ror1嵌合抗原受体
|
|
US20160347848A1
(en)
|
2015-05-28 |
2016-12-01 |
Medimmune Limited |
Therapeutic combinations and methods for treating neoplasia
|
|
DK3303394T3
(da)
*
|
2015-05-29 |
2020-07-06 |
Agenus Inc |
Anti-ctla-4-antistoffer og fremgangsmåder til anvendelse deraf
|
|
GB201512203D0
(en)
|
2015-07-13 |
2015-08-19 |
Lundbeck & Co As H |
Agents,uses and methods
|
|
KR20180029253A
(ko)
|
2015-07-22 |
2018-03-20 |
유레카 쎄라퓨틱스, 인코포레이티드 |
Psa 펩티드/mhc 복합체를 표적화하는 구축물 및 그의 용도
|
|
EP3331917A1
(en)
|
2015-08-04 |
2018-06-13 |
GlaxoSmithKline Intellectual Property Development Limited |
Combination treatments and uses and methods thereof
|
|
TW201713690A
(zh)
|
2015-08-07 |
2017-04-16 |
再生元醫藥公司 |
抗ａｎｇｐｔｌ８抗體及其用途
|
|
CN106620691B
(zh)
*
|
2015-11-04 |
2020-08-21 |
信达生物制药(苏州)有限公司 |
一种重组全人源抗ctla-4单克隆抗体制剂及其应用
|
|
MX2018006072A
(es)
|
2015-11-19 |
2018-08-01 |
Squibb Bristol Myers Co |
Anticuerpos contra receptor de factor de necrosis de tumor inducido por glucocorticoides (gitr) y usos de los mismos.
|
|
CN108367069B
(zh)
|
2015-12-14 |
2022-08-23 |
宏观基因有限公司 |
对于pd-1和ctla-4具有免疫反应性的双特异性分子及其使用方法
|
|
US20190241658A1
(en)
|
2016-01-10 |
2019-08-08 |
Modernatx, Inc. |
Therapeutic mRNAs encoding anti CTLA-4 antibodies
|
|
US11542332B2
(en)
*
|
2016-03-26 |
2023-01-03 |
Bioatla, Inc. |
Anti-CTLA4 antibodies, antibody fragments, their immunoconjugates and uses thereof
|
|
EP4656204A3
(en)
|
2016-04-15 |
2026-06-03 |
BioAtla, Inc. |
Anti-axl antibodies, antibody fragments and their immunoconjugates and uses thereof
|
|
US11596699B2
(en)
|
2016-04-29 |
2023-03-07 |
CureVac SE |
RNA encoding an antibody
|
|
EP3448987A4
(en)
|
2016-04-29 |
2020-05-27 |
Voyager Therapeutics, Inc. |
COMPOSITIONS FOR TREATING A DISEASE
|
|
EP3448874A4
(en)
|
2016-04-29 |
2020-04-22 |
Voyager Therapeutics, Inc. |
COMPOSITIONS FOR TREATING A DISEASE
|
|
IL321475A
(en)
|
2016-05-06 |
2025-08-01 |
Medimmune Llc |
Bispecific binding proteins and their uses
|
|
SG10201603721TA
(en)
|
2016-05-10 |
2017-12-28 |
Agency Science Tech & Res |
Anti-CTLA-4 Antibodies
|
|
EP4122958A1
(en)
|
2016-05-13 |
2023-01-25 |
BioAtla, Inc. |
Anti-ror2 antibodies, antibody fragments, their immunoconjugates and uses thereof
|
|
US10975155B2
(en)
|
2016-05-13 |
2021-04-13 |
Medimmune, Llc |
CD40L-Fc fusion polypeptides and methods of use thereof
|
|
CA3024509A1
(en)
|
2016-05-18 |
2017-11-23 |
Modernatx, Inc. |
Mrna combination therapy for the treatment of cancer
|
|
CA3026151A1
(en)
*
|
2016-06-14 |
2017-12-21 |
Xencor, Inc. |
Bispecific checkpoint inhibitor antibodies
|
|
US10793632B2
(en)
|
2016-08-30 |
2020-10-06 |
Xencor, Inc. |
Bispecific immunomodulatory antibodies that bind costimulatory and checkpoint receptors
|
|
HRP20251424T1
(hr)
*
|
2016-08-30 |
2025-12-19 |
Xencor, Inc. |
Bispecifična imunomodulacijska protutijela koja se vežu na kostimulacijske receptore i receptore imunosnih kontrolnih točaka
|
|
JP7186400B2
(ja)
|
2016-08-30 |
2022-12-09 |
ボード オブ リージェンツ，ザ ユニバーシティ オブ テキサス システム |
ゲノム的に再コードした生物におけるセレノ－生物製剤の製造
|
|
US20180339043A1
(en)
*
|
2017-05-26 |
2018-11-29 |
Janux Therapeutics, Inc. |
Modified antibodies
|
|
KR102834864B1
(ko)
*
|
2018-02-02 |
2025-07-16 |
온코씨4, 아이앤씨. |
개선된 면역치료 효과를 갖지만 약화된 부작용을 갖는 돌연변이 항-ctla-4 항체
|
|
SG11202007018QA
(en)
|
2018-02-02 |
2020-08-28 |
Oncoimmune Inc |
Methods of selecting and designing safer and more effective anti-ctla-4 antibodies for cancer therapy
|
|
SG11202008593PA
(en)
|
2018-03-21 |
2020-10-29 |
Five Prime Therapeutics Inc |
ANTIBODIES BINDING TO VISTA AT ACIDIC pH
|